CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Intraday Update

Markets

Movers

Trading Ideas

AAPG

AEVA

BRZE

CVAC

KULR

ZLAB

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday

Berlin,Kreuzberg,,2022:,The,European,Patent,Office,(epo),,Sub-office,On

Biotech

Health Care

Legal

General

BNTX

CureVac&#39;s amended patent survives BioNTech&#39;s challenge as EPO upholds validity. A German court will decide on infringement in July 2025.

European Patent Office Rules Vaccine Developer CureVac&#39;s Amended Patent Valid, Stock Jumps

Virus,Sample,For,H5n1,(avian,Influenza,Virus),Test,,Avian,Influenza

Large Cap

MRNA

NVAX

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including &#34;pink eye.&#34;

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)

CureVac NV

Events

Press Releases

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Earnings

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell